Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech scientific study

Myotis Bat Genome Longevity Cancer Study

Analysis based on 11 articles · First reported Aug 26, 2026 · Last updated Sep 12, 2026

Sentiment
5
Attention
2
Articles
11
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The study is early-stage basic science with no immediate commercial product, so direct market impact is limited, though it may modestly support sentiment for longevity and oncology-focused biotechnology research. Over time, insights into DNA-damage response and immune gene copy-number variation could inform drug discovery pipelines in aging and cancer therapeutics.

biotechnology pharmaceuticals healthcare

An international research team led by the University of Vermont and Pennsylvania State University published a study in Nature on August 26, 2026, presenting the first near-complete genome assemblies and cell lines for eight Myotis bat species. The work, co-led by Elise Lauterbur and Juan Manuel Vázquez, found that pathogen adaptation, longevity, and cancer resistance are genetically linked in bats. Long-lived bats showed positive selection in pathways related to longevity and cancer, and distinctive adaptation patterns to DNA versus RNA viruses compared with humans and other primates. The little brown bat, Myotis lucifugus, responded to severe DNA damage by increasing programmed cell death rather than DNA repair, a strategy also seen in elephants. Researchers also found that some Myotis species carry two or three copies of the immune gene PKR (EIF2AK2), with duplicated copies contributing to antiviral activity but also greater cellular toxicity. The study was funded by the United States — National Institutes of Health and the United States — National Science Foundation, with co-authors from the University of California, Berkeley, the University of Chicago, the University of Arizona, and the Ecole normale superieure de Lyon. The findings do not provide a treatment for cancer or a method for extending human lifespan, but offer a natural model for studying how immunity, cellular damage, and aging are connected.

per
Co-lead author who collected bat tissue samples, built cell cultures and genomes, and is now at Penn State; central to the study's execution and public communication.
Importance 95.0 Sentiment 10.0
per
Co-lead author at the University of Vermont who identified gene copy-number variation and the link between viral adaptation, longevity, and cancer resistance.
Importance 90.0 Sentiment 10.0
per
Co-author at UC Berkeley studying the genetics of aging and immune response regulation in bat and primate cells.
Importance 50.0 Sentiment 6.0
govactor
Funded the study, supporting basic research into bat genomics, longevity, and disease resistance.
Importance 40.0 Sentiment 5.0
govactor
Funded the study, enabling genome sequencing and cell-line experiments on Myotis bats.
Importance 40.0 Sentiment 5.0
oth
Co-author Lucie Etienne is affiliated with this institution, contributing to the study's comparative genomics work.
Importance 25.0 Sentiment 4.0
per
Co-author from the Ecole normale superieure de Lyon contributing to comparative viral-interaction analysis.
Importance 25.0 Sentiment 4.0
per
Co-author from the University of Arizona contributing to the study's evolutionary genomics analysis.
Importance 25.0 Sentiment 4.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.